HMGCR Cancer Research Results

HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR): Click to Expand ⟱
Source:
Type:
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)
– HMGCR catalyzes the conversion of HMG-CoA to mevalonate, a critical step in the cholesterol biosynthesis pathway.
– Cholesterol is essential for maintaining cell membrane integrity and serves as a precursor for steroid hormones, which can influence tumor growth.

– In certain contexts, elevated HMGCR expression has been linked to more aggressive tumor phenotypes, increased proliferation, and, in some cases, poorer overall survival.


Scientific Papers found: Click to Expand⟱
5454- ATV,    Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- Review, BC, NA
HMG-CoA↓, HMGCR↓, TumCP↓, RadioS↑, CD44↓, P53↑,
5451- ATV,    In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U87MG - in-vitro, GBM, A172
TumAuto↑, CSCs↓, HMG-CoA↓, TumCP↓, tumCV↓, TumCCA↑, TumCG↓, HMGCR↓,
5448- ATV,    Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology
- Review, Var, NA
Apoptosis↑, TumAuto↑, TumCCA↑, BioAv↓, eff↑, HMGCR↓, LDL↓, cardioP↑, AntiTum↑, ChemoSen↑, RadioS↑, toxicity↓,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- Review, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, Synergy↑, OS↑, Remission↑,
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,
8704- BMF,    Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells
- in-vitro, Liver, HepG2 - in-vitro, Colon, Caco-2
TC↓, HMGCR↓,
8703- BMF,    Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
- in-vitro, Var, NA
HMGCR↓, CSCs↓, ALDH↓, STAT3↓, NOTCH↓, Wnt↓, β-catenin/ZEB1↓, OXPHOS↓, FAO↓, selectivity↑, Ingr↝, HMG-CoA↓, Rho↓, p27/CDKN1B↑, mitResp↓, compI↓, compII↓, compIV↓, compV↓, OCR↓, ATP↓,
8407- Lyco,    Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines
- in-vitro, Pca, LNCaP
CholSyn↓, HMGCR↓, RAS↓, NF-kB↓, ROS↓, p‑Jun↓, TumCCA↑, Apoptosis↑, cycD1/CCND1↓, p‑Akt↓, P21↑, p27/CDKN1B↑, P53↑, Bax:Bcl2↑,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

lipid-P↓, 1,   ROS↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   compII↓, 1,   compIV↓, 1,   compV↓, 1,   mitResp↓, 1,   OCR↓, 1,   OXPHOS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↓, 1,   CholSyn↓, 1,   FAO↓, 1,   HMG-CoA↓, 4,   LDL↓, 2,   SREBP2↓, 1,   SREBP2↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 3,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   BIM↑, 1,   Casp↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↓, 1,   PTEN↑, 1,   RAS↓, 2,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HDAC↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   P21↑, 2,   p27/CDKN1B↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 2,   HMGCR↓, 8,   p‑Jun↓, 1,   NOTCH↓, 1,   TumCG↓, 2,   TumCP↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Rho↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   ChemoSen↑, 2,   eff↑, 1,   RadioS↑, 2,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

TC↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   cardioP↑, 1,   OS↑, 1,   Remission↑, 1,   Risk↓, 1,   toxicity↓, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 66

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)
5 Atorvastatin
2 Brutieridin–Melitidin Mixture
1 Dipyridamole
1 Lycopene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1133  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page